Provider groups are on task to create accountable care organizations (ACOs), and many believe they will change the delivery of healthcare
Provider groups are on task to create accountable care organizations (ACOs), and many observers believe they will change the delivery of healthcare in the next decade-although the degree of ACO impact is still greatly debated.
According to Chet Speed, VP, public policy for the American Medical Group Assn. (AMGA), ACOs' greatest potential is to shift the fragmented delivery system toward integration.
However, properly aligned incentives are essential to the success of ACOs. Ideally, it should ease providers away from fee for service.
However, Speed says that if the reimbursement formula is properly crafted, it will generate participation. In addition, there may be some interested parties who will wait until the ACO program has gone through a cycle of experience before joining.
"Over time, it seems likely that the model will evolve into one that employs alternative reimbursement mechanisms-such as partial capitation and bundled payments-and more completely rewards clinical outcomes successes," he says.
According to Speed, the private industry might determine the pathway to make ACOs work-ahead of Medicare. Payers will take advantage of the opportunities to hold providers more accountable for outcomes and quality, shifting a certain amount of financial risk onto the providers.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More